Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: GREG FINLEY who wrote (427)	1/7/2000 8:34:00 AM
From: geewiz	Read Replies (2) \| Respond to of 534

Greg, At the very least we can make three conclusions; Adenovirus trials are on hold, but not naked DNA delivery. Unknown side-effects and mutations; "possible that it did replicate and that it reverted from an allegedly safe third-generation version" If this vector is used in the future, it will need to be delivered in a slow accretive way, not by injection into a vessel: "Antibodies are generally not an issue for intratumoral injections. But, "it's a different story to give the vector intravascularly," Each of these is a positive for the BJCT platform, and not just in the low margin vaccine market, but very high margin biotec delivery market. later, art